ResearcherShanghai Jiao Tong UniversityNo recent work listed

Ling Tian

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1870-8974; OpenAlex author ID A5103107974. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 1)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 4

Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper

Papers 2

Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Last author DOI 10.1016/j.bbcan.2016.08.002 ↗
The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s12253-012-9555-3 ↗

Closest collaborators

The 4 strongest of 4 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Qian Huang · 2 shared papers, 2013–2016 · strength 0.12
- Paper Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. DOI 10.1016/j.bbcan.2016.08.002 ↗
- Paper The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma. DOI 10.1007/s12253-012-9555-3 ↗
Mingjie Jiang · 1 shared paper, 2016 · strength 0.08
- Paper Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. DOI 10.1016/j.bbcan.2016.08.002 ↗
Dian-na Gu · 1 shared paper, 2016 · strength 0.08
- Paper Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. DOI 10.1016/j.bbcan.2016.08.002 ↗
Yanli Luo · 1 shared paper, 2013 · strength 0.04
- Paper The predictive role of p16 deletion, p53 deletion, and polysomy 9 and 17 in pancreatic ductal adenocarcinoma. DOI 10.1007/s12253-012-9555-3 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.